tiprankstipranks
Trending News
More News >
Hogy Medical Co Ltd (JP:3593)
:3593
Advertisement

Hogy Medical Co (3593) AI Stock Analysis

Compare
0 Followers

Top Page

JP:3593

Hogy Medical Co

(OTC:3593)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
Â¥5,103.00
â–¼(-2.24% Downside)
Hogy Medical Co's overall stock score is driven primarily by its strong financial stability and consistent cash flow generation. However, technical analysis suggests potential overbought conditions, and the high P/E ratio indicates a possible overvaluation, which could limit upside potential.

Hogy Medical Co (3593) vs. iShares MSCI Japan ETF (EWJ)

Hogy Medical Co Business Overview & Revenue Model

Company DescriptionHogy Medical Co.,Ltd., together with its subsidiaries, manufactures and sells medical supplies to healthcare facilities in Japan. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, including gowns, personal protective equipment and wearables, drapes, packaged products, instrument table covers, and wraps; and Tigalyer, a multi-layer fabric. The company also provides sterilization products, such as hybrid Mekkin bags, hybrid Mekkin bags ID layered type, and autoclave forceps stand caps; Mekkin cards, which are detection cards used to judge the sterilization process when sterilizing in an autoclave; ethylene oxide gas cards that are detection cards used to judge the sterilization process when sterilizing using ethylene oxide gas; and indicator tapes for autoclave sterilization. In addition, it offers ME equipment operation management system; narcotics/poisons box, an automatic drug reading management system using radio frequency identification; and Securea, a polyurethane sponge for endoscopic surgery. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyHogy Medical Co generates revenue through the sale of its medical and surgical products. The company's primary revenue streams include the production and distribution of surgical gloves, drapes, and procedure kits, which are essential components in surgical and medical procedures. Hogy Medical Co's revenue is driven by its ability to maintain strong relationships with hospitals and healthcare providers, ensuring a steady demand for its high-quality and reliable products. Additionally, the company may benefit from strategic partnerships and collaborations that enhance its market presence and access to new technologies, although specific details about such partnerships are not readily available.

Hogy Medical Co Financial Statement Overview

Summary
Hogy Medical Co exhibits financial stability with a solid balance sheet, low debt, and strong cash flow generation. Despite some decline in profitability margins, the company's revenue and gross margin performance remain solid, supported by low leverage and a high equity ratio.
Income Statement
75
Positive
Hogy Medical Co shows solid revenue stability with a slight increase in revenue over the years. The Gross Profit Margin is consistently strong, indicating effective cost management. However, there's a notable decline in Net Profit Margin and EBIT Margin in the latest year compared to prior periods, suggesting increased operational costs or lower pricing power. The EBITDA Margin remains robust, highlighting strong earnings before accounting for interest, taxes, depreciation, and amortization.
Balance Sheet
82
Very Positive
The company maintains a healthy balance sheet with a very low Debt-to-Equity Ratio, indicating low financial leverage. The Return on Equity has seen some fluctuation but remains positive, reflecting efficient use of equity capital. The Equity Ratio is high, signifying strong financing through equity and low reliance on debt, which provides financial stability.
Cash Flow
78
Positive
Hogy Medical Co exhibits strong cash flow with consistent Free Cash Flow generation and growth in Operating Cash Flow. The Free Cash Flow to Net Income Ratio indicates solid cash generation relative to net income, despite some variability in Free Cash Flow growth over the years. The Operating Cash Flow to Net Income Ratio showcases the company's ability to convert net income into cash effectively.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue39.14B39.14B39.10B38.98B36.78B36.50B
Gross Profit12.62B12.62B12.49B15.74B15.42B15.33B
EBITDA9.69B8.75B10.71B10.25B10.25B10.18B
Net Income1.52B1.52B2.80B4.32B4.37B4.96B
Balance Sheet
Total Assets97.89B97.89B100.04B102.18B98.97B105.64B
Cash, Cash Equivalents and Short-Term Investments22.00B22.00B19.42B18.86B14.36B20.55B
Total Debt13.67B13.67B5.82B8.89B10.00B330.00M
Total Liabilities23.56B23.56B13.92B18.50B18.97B9.69B
Stockholders Equity74.32B74.32B86.11B83.61B79.96B95.88B
Cash Flow
Free Cash Flow6.53B6.53B4.32B7.78B5.30B-686.00M
Operating Cash Flow11.76B11.76B7.12B9.18B8.50B6.85B
Investing Cash Flow-4.12B-4.12B-3.26B-1.95B-3.81B-6.95B
Financing Cash Flow-5.46B-5.46B-3.89B-3.14B-11.05B-2.50B

Hogy Medical Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5220.00
Price Trends
50DMA
4804.10
Positive
100DMA
4377.42
Positive
200DMA
4529.66
Positive
Market Momentum
MACD
90.81
Positive
RSI
54.55
Neutral
STOCH
35.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3593, the sentiment is Positive. The current price of 5220 is below the 20-day moving average (MA) of 5284.50, above the 50-day MA of 4804.10, and above the 200-day MA of 4529.66, indicating a neutral trend. The MACD of 90.81 indicates Positive momentum. The RSI at 54.55 is Neutral, neither overbought nor oversold. The STOCH value of 35.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3593.

Hogy Medical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
144.86B17.886.62%3.62%2.72%-6.31%
75
Outperform
125.12B22.9412.01%3.07%5.82%-20.09%
73
Outperform
177.22B34.457.08%2.51%10.98%-76.45%
69
Neutral
$73.65B90.571.63%1.61%-0.91%-52.71%
60
Neutral
19.15B13.836.72%2.32%11.12%20.54%
60
Neutral
11.12B-40.090.22%3.74%3.36%-310.49%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3593
Hogy Medical Co
5,220.00
924.95
21.54%
DE:6SN
Nakanishi
11.90
-3.42
-22.32%
PBHDF
Paramount Bed Holdings Co
18.32
1.20
7.01%
JP:3154
Medius Holdings Co., Ltd.
861.00
49.92
6.15%
JP:7702
JMS Co., Ltd.
456.00
-31.95
-6.55%
JP:7730
Mani, Inc.
1,270.00
-499.62
-28.23%

Hogy Medical Co Corporate Events

Hogy Medical Co. Clarifies Privatization Speculation
Jul 28, 2025

Hogy Medical Co., Ltd. addressed recent media reports suggesting its potential privatization, clarifying that while it is considering various options to enhance corporate value, no official decision has been made. This announcement indicates the company’s strategic exploration to potentially reposition itself in the market, though stakeholders should note that no concrete plans have been finalized.

Hogy Medical Co. Reports Decline in Q1 2025 but Projects Growth
Jul 25, 2025

Hogy Medical Co., Ltd. reported a decline in its financial performance for the three months ended June 30, 2025, with net sales and profits decreasing compared to the previous year. Despite the downturn, the company plans to increase its annual dividends per share and forecasts a positive growth in net sales and profits for the full fiscal year ending March 31, 2026, indicating a strategic focus on long-term growth and shareholder value.

Hogy Medical Co. Announces Shareholder Meeting Outcomes
Jun 20, 2025

Hogy Medical Co., Ltd. announced the results of its 64th Annual General Meeting of Shareholders, where the proposal for the election of directors was approved. Although one director candidate nominated by shareholders was elected, the company noted that this individual does not meet its criteria for independence. The newly elected director is expected to strengthen management oversight, contributing from a unique perspective compared to the current independent directors.

Hogy Medical Announces Leadership Restructuring
Jun 20, 2025

Hogy Medical Co., Ltd. announced significant changes to its Board of Directors and executive officers, effective June 20, 2025, and July 1, 2025, respectively. These changes are expected to enhance the company’s leadership structure, potentially impacting its strategic direction and operational efficiency, which could have implications for stakeholders and the company’s market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 29, 2025